Brokers Offer Predictions for UNCY FY2024 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at Brookline Capital Management increased their FY2024 earnings estimates for Unicycive Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($0.03) for the year, up from their previous estimate of ($0.08). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q4 2024 earnings at ($0.07) EPS and FY2025 earnings at ($0.15) EPS.

Several other equities research analysts also recently weighed in on UNCY. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. HC Wainwright reiterated a “buy” rating and set a $2.50 price target on shares of Unicycive Therapeutics in a research note on Tuesday, November 12th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $5.13.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $0.46 on Monday. The company has a market capitalization of $47.75 million, a P/E ratio of -0.47 and a beta of 2.29. The company’s 50 day moving average price is $0.43 and its 200-day moving average price is $0.54. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.82.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in Unicycive Therapeutics in the 1st quarter worth approximately $36,000. XTX Topco Ltd bought a new position in shares of Unicycive Therapeutics in the third quarter worth approximately $29,000. Bleakley Financial Group LLC purchased a new position in shares of Unicycive Therapeutics in the third quarter valued at about $33,000. Acuta Capital Partners LLC purchased a new position in Unicycive Therapeutics during the 3rd quarter valued at about $807,000. Finally, BVF Inc. IL raised its position in Unicycive Therapeutics by 70.5% during the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after purchasing an additional 1,493,462 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.